1
EXHIBIT 10.69
FIRST AMENDMENT TO CHANGE OF CONTROL SEVERANCE AGREEMENT
Reference is made to that certain Agreement dated March 24, 1997 between
the undersigned, Xxxx Xxxxx, as "Executive" and the Company.
Based on good and valid consideration, the receipt and sufficiency of
which is hereby acknowledged, and with the intent to be bound hereby, the
parties agree as follows:
(1) The first sentence of the Agreement is hereby amended and restated in
full as follows:
THIS AGREEMENT dated as of March 24, 1997, is made by and between the
Company and Xxxx Xxxxx (the "Executive").
(2) The second "WHEREAS" clause of the Agreement is hereby amended and
restated in full as follows:
WHEREAS the Board of Directors of Wang Laboratories, Inc. (the "Board")
recognizes that, as is the case with many publicly-held corporations, the
possibility of a Change in Control (as defined in the last Section hereof)
exists and that such possibility, and the uncertainty and questions which it may
raise among such management, may result in the departure or distraction of
management personnel to the detriment of the Company and its shareholders; and
(3) The first sentence of Paragraph 2 of the Agreement is hereby amended and
restated in full as follows:
2. TERMS OF AGREEMENT. This Agreement, which commenced as of March 24,
1997, shall be renewed as of July 1, 1998 (the "Renewal Date") and shall
continue in effect while the Executive is employed by the Company for a period
of three years from the Renewal Date, provided, however, that commencing on the
second anniversary of the Renewal Date and on each anniversary thereafter, the
term of this Agreement shall automatically be extended for one additional year
unless, not later than ninety days prior to any such anniversary date either
party shall have given notice that it does not wish to extend this Agreement
(provided that no such notice may be given by the Company during the pendency of
or within one year following a Potential Change in Control); provided, further,
if a Change in Control shall have occurred during the original, renewed or
extended term of this Agreement, this Agreement shall continue in effect for a
period of thirty-six months beyond the month in which such Change in Control
occurred.
(4) In Paragraph 6.1 of the Agreement, the phrase "equal to 2.99 times the
average of the Executive's base salary and annual bonus received in" is hereby
amended and restated as: "equal to 2.99 times the average of the Executive's
base salary and annual bonus paid in...."
2
(5) Section (A) of Paragraph 16 of the Agreement is hereby amended and
restated in full as follows:
(A) "Affiliate" shall mean an entity that is controlled by Wang
Laboratories, Inc.
(6) Paragraph 16 of the Agreement is hereby amended to add Section 16(A1) as
follows:
(A1) "Base Amount" shall have the meaning defined in section 280G(b)(3)
of the Code.
(7) Section (C) of Paragraph 16 of the Agreement is hereby amended and
restated in full as follows:
(C) "Board" shall mean the Board of Directors of Wang Laboratories,
Inc.
(8) Section (ii) of paragraph 16(E) of the Agreement is hereby amended and
restated in full as follows:
(ii) during any period of twenty-four consecutive months (not including
any period prior to the execution of this Agreement), individuals who at the
beginning of such period constitute the Board and any new director (other than a
director whose initial assumption of office is in connection with an actual or
threatened election contest, including but not limited to a consent
solicitation, relating to the election of directors of the company) whose
election by the Board or nomination for election by the Company's stockholders
was approved by a vote of at least two-thirds (2/3) of the directors then still
in office who either were directors at the beginning of the period or whose
election was previously so approved, cease for any reason to constitute a
majority thereof; or
(9) The following language is hereby inserted, so as to replace the existing
language, before subsection (i) of Section (E)(iii) of Paragraph 16 of the
Agreement:
(iii) the Company or any Subsidiary or Affiliate merges or consolidates
with any other corporation, other than
(10) Section (E)(iv) of Paragraph 16 of the Agreement is hereby amended and
restated in full as follows:
(iv) the shareholders of the Company approve a plan of complete
liquidation of the Company or there is consummated the sale or disposition by
the Company of all or substantially all of the Company's assets or the Company
is dissolved and its assets distributed in a judicial proceeding.
Page 2 of 3
3
(11) Section (G) of Paragraph 16 of the Agreement is hereby amended and
restated in full as follows:
(G) Except with respect to Sections 16(E) and (N) hereof, "Company"
shall mean Wang Laboratories, Inc. or one of its Subsidiaries or Affiliates,
both as defined herein, and any successor to their business and/or assets which
assumes and agrees to perform this Agreement by operation of law, or otherwise.
For the purposes of Sections 16(E) and (N) hereof, "Company" shall mean Wang
Laboratories, Inc. and any successors thereto or any parent thereof.
(12) Paragraph 16 of the Agreement shall be amended to add Section 16(P1) as
follows:
(P1) "Subsidiary" shall mean an entity that is controlled by Wang
Laboratories, Inc.
The parties hereby ratify the Agreement as amended hereby without further
changes. This Amendment to the Agreement is executed as a document under seal
this __ day of August, 1998.
WANG LABORATORIES, INC.
By: _________________________
Xxxxxx X. Xxxxx
Chairman of the Board and
Chief Executive Officer
and
AGREED:
By: ______________________
Xxxx Xxxxx
Page 3 of 3
